Abstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Keywords:
COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17.
Copyright © 2020. Published by Elsevier B.V.
MeSH terms
-
Betacoronavirus / immunology
-
COVID-19
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / pathology
-
Cytokine Release Syndrome / drug therapy*
-
Cytokines / biosynthesis
-
Cytokines / immunology
-
Humans
-
Janus Kinase 2 / antagonists & inhibitors*
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / pathology
-
Pyrrolidines / pharmacology*
-
SARS-CoV-2
-
Sulfonamides / pharmacology*
-
Th17 Cells / immunology*
Substances
-
Cytokines
-
Pyrrolidines
-
Sulfonamides
-
fedratinib
-
JAK2 protein, human
-
Janus Kinase 2